**Background**
Bacterial infections caused by both Gram-negative and Gram-positive pathogens remain a significant global health challenge. Among these, Mycobacterium tuberculosis and Klebsiella pneumoniae are particularly formidable due to their ability to cause severe respiratory distress and their potential for drug resistance. Effective treatment requires agents that can penetrate bacterial defenses and disrupt essential cellular processes. The inhibition of protein synthesis is a primary strategy in antibacterial therapy, specifically by targeting the bacterial ribosome to prevent the translation of critical proteins. In this context, we will introduce an orally active antibacterial agent – Kanamycin.
**Definition**
Kanamycin (Kanamycin A) sulfate is an antibacterial agent that inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. According to the Kanamycin description, it exhibits potent inhibitory activity against both sensitive and drug-resistant strains of M. tuberculosis as well as K. pneumoniae.
**In Vitro and In Vivo Studies**
The Kanamycin biological activity has been extensively evaluated across various models. In terms of Kanamycin in vitro studies, the compound (0.1-100 μg/mL; 2 weeks) demonstrated strong antibacterial activity against multiple strains of mycobacteria, including H37Rv, H2, H37RvR-PAS, Ravenel, and BCG, with minimum inhibitory concentrations (MIC) of 1 μg/mL, while the Kirchbergand strain showed an MIC of 5 μg/mL.
Regarding Kanamycin In Vivo efficacy, research using inbred normal mice infected with bovine tubercle bacilli (Ravenel strain) showed that subcutaneous administration of Kanamycin sulfate (2, 4 mg/kg; once daily, 6 times a week for 3 weeks) markedly inhibited the multiplication of tuberculosis, particularly within the lungs and spleen. Furthermore, in Slc:ICR male mice infected with K. pneumoniae DT-S via the aerosol method, a single subcutaneous dose (1.25, 5 mg/kg) administered 3 hours post-infection suppressed bacterial growth in the lung, trachea, and blood in a dose-dependent manner. Notably, a dosage of 5 mg/kg resulted in a 90% survival rate at 6 days post-infection and cleared the pathogen from the respiratory tract and blood within 48 hours. In conclusion, Kanamycin is a potent aminoglycoside antibiotic effective for the study and treatment of mycobacterial and pneumonia-related infections.
Keywords
Kanamycin, 25389-94-0, Kanamycin A, Bacterial, Antibiotic, tuberculosis, mycobacteria, bovine tubercle bacilli, streptomycin, K. pneumonia, pneumonia, Inhibitor, inhibitor, inhibit
References
[1] YANAGISAWA K, et al. Studies on kanamycin, a new antibiotic against tubercle bacilli. I. Effect on virulent tubercle bacilli in vitro and in mice. J Antibiot (Tokyo). 1957 Nov;10(6):233-5.
[2] Nishi T, et al. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin. Antimicrob Agents Chemother. 1980 Mar;17(3):494-505.
[3] Misumi M, et al. Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. Biochem Biophys Res Commun. 1978 Sep 29;84(2):358-65.
[4] Misumi M, et al. Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid. Biochem Biophys Res Commun. 1980 Jan 29;92(2):647-54.